Literature DB >> 29614633

Vascular complications of sickle cell disease.

Ashar Usmani1, Roberto F Machado2.   

Abstract

Sickle cell disease (SCD) is a monogenetic disorder caused by a mutation in the β-globin gene HBB leading to polymerization of red blood cells causing damage to cell membranes, increasing its rigidity and intravascular hemolysis. Multiple lines of evidence suggest that SCD can be viewed as pan-vasculopathy associated with multiple mechanisms but driven by hemoglobin S polymerization. Here we review the pathophysiology, clinical manifestations and management strategies for cerebrovascular disease, pulmonary hypertension and renal disease associated with SCD. These "vascular phenotypes" reflect the systemic nature of the complications of SCD and are a major threat to the well-being of patients with the disorder.

Entities:  

Keywords:  Sickle cell disease; cerebral vasculopathy; nitric oxide; pulmonary hypertension; renal disease

Mesh:

Substances:

Year:  2018        PMID: 29614633      PMCID: PMC7194475          DOI: 10.3233/CH-189008

Source DB:  PubMed          Journal:  Clin Hemorheol Microcirc        ISSN: 1386-0291            Impact factor:   2.375


  140 in total

1.  Comparison of the inhibitory potencies of N(G)-methyl-, N(G)-nitro- and N(G)-amino-L-arginine on EDRF function in the rat: evidence for continuous basal EDRF release.

Authors:  H M Vargas; J M Cuevas; L J Ignarro; G Chaudhuri
Journal:  J Pharmacol Exp Ther       Date:  1991-06       Impact factor: 4.030

Review 2.  Cytokines and plasma factors in sickle cell disease.

Authors:  Julia E Brittain; Leslie V Parise
Journal:  Curr Opin Hematol       Date:  2007-09       Impact factor: 3.284

3.  Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes.

Authors:  Laura M De Castro; Jude C Jonassaint; Felicia L Graham; Allison Ashley-Koch; Marilyn J Telen
Journal:  Am J Hematol       Date:  2008-01       Impact factor: 10.047

4.  A hemodynamic study of pulmonary hypertension in sickle cell disease.

Authors:  Florence Parent; Dora Bachir; Jocelyn Inamo; François Lionnet; Françoise Driss; Gylna Loko; Anoosha Habibi; Soumiya Bennani; Laurent Savale; Serge Adnot; Bernard Maitre; Azzedine Yaïci; Leila Hajji; Dermot S O'Callaghan; Pierre Clerson; Robert Girot; Frederic Galacteros; Gerald Simonneau
Journal:  N Engl J Med       Date:  2011-07-07       Impact factor: 91.245

Review 5.  Cardiovascular effects of anemia.

Authors:  M A Varat; R J Adolph; N O Fowler
Journal:  Am Heart J       Date:  1972-03       Impact factor: 4.749

6.  Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines.

Authors:  R De Caterina; P Libby; H B Peng; V J Thannickal; T B Rajavashisth; M A Gimbrone; W S Shin; J K Liao
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

7.  Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension.

Authors:  Kenneth I Ataga; Charity G Moore; Cheryl A Hillery; Susan Jones; Herbert C Whinna; Dell Strayhorn; Cathy Sohier; Alan Hinderliter; Leslie V Parise; Eugene P Orringer
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

8.  The use of transcranial ultrasonography to predict stroke in sickle cell disease.

Authors:  R Adams; V McKie; F Nichols; E Carl; D L Zhang; K McKie; R Figueroa; M Litaker; W Thompson; D Hess
Journal:  N Engl J Med       Date:  1992-02-27       Impact factor: 91.245

Review 9.  Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Authors:  Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272

10.  Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.

Authors:  Mark T Gladwin; Vandana Sachdev; Maria L Jison; Yukitaka Shizukuda; Jonathan F Plehn; Karin Minter; Bernice Brown; Wynona A Coles; James S Nichols; Inez Ernst; Lori A Hunter; William C Blackwelder; Alan N Schechter; Griffin P Rodgers; Oswaldo Castro; Frederick P Ognibene
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

View more
  4 in total

Review 1.  cGMP modulation therapeutics for sickle cell disease.

Authors:  Nicola Conran; Lidiane Torres
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-28

Review 2.  Microfluidic methods to advance mechanistic understanding and translational research in sickle cell disease.

Authors:  Melissa Azul; Eudorah F Vital; Wilbur A Lam; David K Wood; Joan D Beckman
Journal:  Transl Res       Date:  2022-03-27       Impact factor: 10.171

3.  Antiphospholipid Antibodies in Sickle Cell Disease: A Systematic Review and Exploratory Meta-Analysis.

Authors:  Mira Merashli; Alessia Arcaro; Maria Graf; Matilde Caruso; Paul R J Ames; Fabrizio Gentile
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

4.  Chronic anemia: The effects on the connectivity of white matter.

Authors:  Clio González-Zacarías; Soyoung Choi; Chau Vu; Botian Xu; Jian Shen; Anand A Joshi; Richard M Leahy; John C Wood
Journal:  Front Neurol       Date:  2022-07-26       Impact factor: 4.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.